Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 60 Records) |
Query Trace: Breast Neoplasms and CDK4[original query] |
---|
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer. Frontiers in pharmacology 2022 8 13 897951. Roncato Rossana, Gerratana Lorenzo, Palmero Lorenza, Gagno Sara, Poetto Ariana Soledad, Peruzzi Elena, Zanchetta Martina, Posocco Bianca, De Mattia Elena, Canil Giovanni, Alberti Martina, Orleni Marco, Toffoli Giuseppe, Puglisi Fabio, Cecchin Eri |
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis. Cancers 2022 8 14 (16): . Rossi Tania, Angeli Davide, Tebaldi Michela, Fici Pietro, Rossi Elisabetta, Rocca Andrea, Palleschi Michela, Maltoni Roberta, Martinelli Giovanni, Fabbri Francesco, Gallerani Giul |
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. Cancers 2022 7 14 (13): . Lee Jin Sun, Yost Susan E, Li Sierra Min, Cui Yujie, Frankel Paul H, Yuan Yate-Ching, Schmolze Daniel, Egelston Colt A, Guo Weihua, Murga Mireya, Chang Helen, Bosserman Linda, Yuan Yu |
CCND1 Copy Number Variation in Circulating Tumor DNA from Luminal B Breast Cancer Patients. Anticancer research 2022 7 42 (8): 4071-4077. Shimazaki Akiko, Kubo Makoto, Kurata Kanako, Takao Yuka, Hayashi Saori, Harada Yurina, Kawaji Hitomi, Kaneshiro Kazuhisa, Yamada Mai, Kai Masaya, Nakamura Masafu |
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. European journal of clinical pharmacology 2022 May . Maeda Akimitsu, Ando Hitoshi, Irie Kei, Hashimoto Naoya, Morishige Jun-Ichi, Fukushima Shoji, Okada Akira, Ebi Hiromichi, Matsuzaki Masahide, Iwata Hiroji, Sawaki Masata |
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 4 28 (11): 2248-2256. Lim Joline S J, Wong Andrea L A, Ow Samuel G W, Ngoi Natalie Y L, Chan Gloria H J, Ang Yvonne L E, Chong Wan Qin, Lim Siew Eng, Lim Yi Wan, Lee Matilda, Choo Joan R E, Tan Hon Lyn, Yong Wei Peng, Soo Ross A, Tan David S P, Chee Cheng Ean, Sundar Raghav, Yadav Kritika, Jain Supriya, Wang Lingzhi, Tai Bee Choo, Goh Boon Cher, Lee Soo-Ch |
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. JCO precision oncology 2022 3 6 e2100140. Bruno Luisina, Ostinelli Alexis, Waisberg Federico, Enrico Diego, Ponce Carolina, Rivero Sergio, Blanco Albano, Zarba Martín, Loza Martín, Fabiano Verónica, Amat Mora, Pombo María Teresa, Noro Laura, Chacón Matías, Coló Federico, Chacón Reinaldo, Nadal Jorge, Nervo Adrián, Costanzo Victor |
Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. Oncology research and treatment 2022 2 45 (5): 248-253. Decker Thomas, Bichler Matthias, Birtel Andrea, Fischer Gerhard, Geiger Kathrin, Gaenger Stella, Nonnenbroich Christoph, Dechow Tobias, Muendlein Ax |
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer science 2022 2 113 (5): 1808-1820. Chin Yoon Ming, Shibayama Tomoko, Chan Hiu Ting, Otaki Masumi, Hara Fumikata, Kobayashi Takayuki, Kobayashi Kokoro, Hosonaga Mari, Fukada Ippei, Inagaki Lina, Ono Makiko, Ito Yoshinori, Takahashi Shunji, Ohno Shinji, Ueno Takayuki, Nakamura Yusuke, Low Siew-K |
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO precision oncology 2022 2 1 1-12. Kurian Allison W, Hughes Elisha, Handorf Elizabeth A, Gutin Alexander, Allen Brian, Hartman Anne-Renee, Hall Michael |
Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast (Edinburgh, Scotland) 2022 11 66 255-261. Zhou Jinmei, Wu Xuexue, Zhang Huiqiang, Wang Xiaobo, Yuan Yang, Zhang Shaohua, Jiang Zefei, Wang T |
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO precision oncology 2022 10 6 e2200149. Sammons Sarah, Raskina Kira, Danziger Natalie, Alder Laura, Schrock Alexa B, Venstrom Jeffrey M, Knutson Keith L, Thompson E Aubrey, McGregor Kim, Sokol Ethan, Chumsri Saran |
Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. Frontiers in oncology 2022 10 12 986674. Guan Yin, Wang Yutong, Li Hongxia, Meng Jing, You Xia, Zhu Xiaofeng, Zhang Qin, Sun Tingting, Qi Chuang, An Guangyu, Fan Ying, Xu Bing |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of oncology : official journal of the European Society for Medical Oncology 2023 9 . F André, F Su, N Solovieff, G Hortobagyi, S Chia, P Neven, A Bardia, D Tripathy, Y-S Lu, A Lteif, T Taran, N Babbar, D Slamon, C L Artea |
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 9 167 115479. Elena Peruzzi, Lorenzo Gerratana, Marcella Montico, Bianca Posocco, Serena Corsetti, Michele Bartoletti, Sara Gagno, Marco Orleni, Elena De Mattia, Massimo Baraldo, Erika Cecchin, Fabio Puglisi, Giuseppe Toffoli, Rossana Ronca |
Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. Frontiers in oncology 2023 9 13 1192946. Ta-Chung Chao, Yi-Fang Tsai, Chun-Yu Liu, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Jiun-I Lai, Chih-Yi Hsu, Jiun Jen Lynn, Chi-Cheng Huang, Ling-Ming Tse |
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Annals of oncology : official journal of the European Society for Medical Oncology 2023 8 . K Jhaveri, L D Eli, H Wildiers, S A Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, E S Yang, I Spanggaard, S Reid, M E Burkard, S Vinayak, A Prat, M Arnedos, F-C Bidard, S Loi, J Crown, M Bhave, S A Piha-Paul, J M Suga, S Chia, C Saura, J Á Garcia-Saenz, V Gambardella, M J de Miguel, E N Gal-Yam, A Rapael, S M Stemmer, C Ma, A B Hanker, D Ye, J W Goldman, R Bose, L Peterson, J S K Bell, A Frazier, D DiPrimeo, A Wong, C L Arteaga, D B Sol |
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors. International journal of molecular sciences 2023 7 24 (14): . Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáe |
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome medicine 2023 7 15 (1): 55. Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A Rejto, Woong-Yang Park, Zhengyan K |
Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M Litchfield, Lee Bowman, Garreth W Lawrence, Amit Aggarwal, Fabrice And |
Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 OF1-OF7. Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Mill |
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology 2023 5 7 e2200531. Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Carolina Reduzzi, Katherine Clifton, Leslie Bucheit, Whitney L Hensing, Ami N Shah, Tania Pivetta, Charles S Dai, Paolo D'Amico, Firas Wehbe, Arielle Medford, Seth A Wander, William J Gradishar, Amir Behdad, Cynthia X Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanil |
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British journal of cancer 2023 4 . Frenel J-S, Lusque A, Delaloge S, Ferrero J-M, Bachelot T, Desmoulins I, Levy C, Eymard J-C, Gonçalves A, Patsouris A, Reynier M A Mouret, Thery M J-C, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge |
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England) 2023 4 . Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bida |
HR/HER2 de novo metastatic breast cancer: a true peculiar entity? Drugs in context 2023 3 12 . Torrisi Rosalba, Jacobs Flavia, Miggiano Chiara, De Sanctis Rita, Santoro Arman |
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer. JNCI cancer spectrum 2023 2 . Mouron Silvana, Bueno Maria J, Muñoz Manuel, Torres Raul, Rodríguez Sandra, Apala Juan V, Silva Jorge, Sánchez-Bayona Rodrigo, Manso Luis, Guerra Juan, Rodriguez-Lajusticia Laura, Malon Diego, Malumbres Marcos, Quintela-Fandino Migu |
Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first-line setting. Cancer reports (Hoboken, N.J.) 2023 12 e1966. R Gencheva, M Petrova, P Kraleva, S Hadjidekova, M Radanova, N Conev, D Stoyanov, J Arabadjiev, E Tazimova, S Bachurska, M Eneva, M Tsvetkova, G Zhbantov, T Karanikolova, D Manov, A Ivanova, M Taushanova-Hadjieva, R Staneva, E Dimitrova, I Don |
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The oncologist 2023 11 . Jiun-I Lai, Ting-Hao Kuo, Kuan-Jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Ch |
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023 1 . Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra M-A, Delaloge S, Robert L, Cottu P, Pierga J Y, Loirat D, Bertucci A, Renouf B, Bidard F C, Lerebours |
Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 1 . Davis Andrew A, Luo Jingqin, Zheng Tiantian, Dai Chao, Dong Xiaoxi, Tan Lu, Suresh Rama, Ademuyiwa Foluso O, Rigden Caron, Rearden Timothy P, Clifton Katherine, Weilbaecher Katherine, Frith Ashley, Tandra Pavankumar K, Summa Tracy, Haas Brittney, Thomas Shana, Hernandez-Aya Leonel F, Peterson Lindsay L, Wang Xiaohong, Luo Shujun J, Zhou Kemin, Du Pan, Jia Shidong, King Bonnie L, Krishnamurthy Jairam, Ma Cynthia |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: